# Bone Marrow-derived Human Mesenchymal Stem Cell Production in Corning<sup>®</sup> HYPERStack<sup>®</sup> 36-layer Cell Culture Vessels

# **Application Note**

Hilary Sherman and John Shyu Corning Incorporated, Life Sciences Kennebunk, ME USA

## Introduction

Mesenchymal stem cells (MSCs) are multipotent cells that have recently generated significant interest for cellular therapy applications. MSCs have the potential to differentiate into other mesenchymal tissue lineages such as adipocytes, osteocytes, and chondrocytes<sup>1</sup>. Additionally, they are known to secrete trophic factors that can play an important role in immunoregulation<sup>1</sup>. Although MSCs can be isolated from different tissue sources, bone marrow-derived MSCs are commonly studied due to their ease of access and achievable therapeutic dosage (2 x 10<sup>6</sup> cells/kb of body weight)<sup>2,3</sup>. Here, we demonstrate the utility of the Corning HYPERStack 36-layer cell culture vessel as a tool to meet the growing demand for expanding bone marrow-derived MSCs to relevant scale for clinical application workflows. The utilization of gas permeable film technology provided in the spatial footprint of a traditional stacked cell culture vessel enables Corning HYPERStack cell culture vessels to provide up to 5X the surface area in the same spatial footprint for expansion of adherent cell types, such as MSCs. Our results show that over 870 million human bone marrow-derived MSCs can be obtained from a single HYPERStack 36-layer cell culture vessel. Furthermore, harvested cells demonstrated high viability and expressed characteristic surface markers of human bone marrow-derived MSC identity.

## **Materials and Methods**

Human bone marrow-derived MSCs (RoosterBio Cat. No. MSC-1M-5XF) were thawed into T-175 flasks (Corning Cat. No. 431080) containing RoosterNourish™-MSC-XF (RoosterBio Cat. No. KT-016) per vendor's recommended protocol. Upon achieving 90% confluence, cells were harvested with TrypLE™ Express Enzyme (ThermoFisher Cat. No. 12604021) and centrifuged at 200 x g for 10 minutes. Cells were re-plated in Falcon<sup>®</sup> 875 cm<sup>2</sup> Multi-Flasks (Corning Cat. No. 353144) at a density of 3 x 10<sup>3</sup> cells/cm<sup>2</sup>. After five days of culturing in a humidified, 5%  $CO_2$  incubator at 37°C, cells were harvested as previously described and seeded into pre-warmed Corning HYPERStack 36-layer cell culture vessels (Corning Cat. No. 20036) at 3 x 10<sup>3</sup> cells/cm<sup>2</sup>. It is recommended to pre-warm the Corning HYPERStack 36-layer cell culture vessel at 37°C to prevent any temperature gradients during the seeding process. Human bone marrow-derived MSCs were expanded in the HYPERStack cell culture vessels for five days, then Cells were harvested and assessed for yield and viability. The expansion from cryogenic vial thaw through HYPERStack 36-layer cell culture vessel expansion was repeated three independent times. To confirm MSC identity, approximately  $1 \times 10^7$  cells were stained (BD Biosciences Cat. No. 562245) per vendor protocol and CD surface antigens assessed via flow cytometry.

CORNING

## **Results and Discussion**

Human bone marrow-derived MSC densities ranging from 4.4 x 10<sup>4</sup> to 5.2 x 10<sup>4</sup> cells/cm<sup>2</sup> were achieved after 5 days of culture in Corning HYPERStack 36-layer cell culture vessels (Figure 1). The average of all three studies resulted in a total MSC yield of more than 8.7 x 10<sup>8</sup> cells per HYPERStack 36-layer cell culture vessel. For therapeutic application workflows, it is essential to recover MSCs that have high viability and express appropriate surface markers<sup>4</sup>. In these studies, MSCs collected from HYPERStack 36-layer cell culture vessels showed greater than 90% average viability (Figure 1). The International Society for Cellular Gene Therapy (ISCT) has defined the minimal criteria for human bone marrow-derived MSC quality as expressing >95% of CD105, CD73, and CD90 and lack of expression (<2%) of typical hematopoietic markers CD45, CD34, CD14 or CD11b, CD79a or CD19, and HLA-DR surface molecules<sup>4</sup>. Human bone marrow-derived MSCs recovered from HYPERStack 36-layer cell culture vessels were characterized via flow cytometry, and displayed greater than 99% expression of CD90, CD105 and CD73 while expressing less than a half a percent of negative markers (CD45, CD34, CD11b, CD19, and HLA-DR).



**Figure 1.** Human bone marrow-derived MSC yields and viability from Corning HYPERStack 36-layer cell culture vessels. Bars are cell density and dots are viability.



**Figure 2.** Surface marker characterization of human bone marrow-derived MSCs expanded in Corning HYPERStack 36-layer cell culture vessels. Representative marker expression from one study. Sample (blue) compared to isotype control (black). Negative markers are a cocktail of CD45, CD34, CD11b, CD19, and HLA-DR.

#### **Conclusions**

The growing number of clinical trials involving stem cells used for therapeutic applications has led to an increase in demand for tools and technologies that enable efficient scale-up of stem cells, without compromising cell viability and cell health. Here we demonstrate that the Corning® HYERStack® 36-layer cell culture vessels offers an effective method for expanding large quantities of human bone marrow-derived MSCs that maintain high viability and appropriate surface marker characterization.

#### References

- Kassem M. Mesenchymal stem cells: biological characteristics and potential clinical applications. Cloning and Stem Cells (2004) 6.4:369-374.
- Musiał-Wysocka A, Kot M, and Majka M. The pros and cons of mesenchymal stem cell-based therapies. Cell Transplant (2019) 28.7:801-812.
- 3. Hassan M, et al. Large-scale expansion of human mesenchymal stem cells. Stem Cells International (2020).
- Robb KP, et al. Mesenchymal stromal cell therapy: progress in manufacturing and assessments of potency. Cytotherapy (2019) 21.3:289-306.

For more specific information on claims, visit www.corning.com/certificates.

Warranty/Disclaimer: Unless otherwise specified, all products are for research use or general laboratory use only.\* Not intended for use in diagnostic or therapeutic procedures. Not for use in humans. These products are not intended to mitigate the presence of microorganisms on surfaces or in the environment, where such organisms can be deleterious to humans or the environment. Corning Life Sciences makes no claims regarding the performance of these products for clinical or diagnostic applications. \*NOTE: The following products and their sterile accessories are considered US class I medical devices: Tissue culture plates, flasks and dishes (area >100 cm<sup>2</sup>), multilayer flasks, spinner flasks, Erlenmeyer flasks, Corning HYPERFlask and HYPERStack vessels, Corning CellSTACK chambers, centrifuge tubes, cell culture tubes, cryogenic vials, roller bottles, polystyrene microcarrier beads. Falcon IVF products are US class II and CE marked per the EU medical device directive 93/42/EEC.

# CORNING

Corning Incorporated Life Sciences

www.corning.com/lifesciences

t 800.492.1110 t 978.442.2200 ASIA/PACIFIC

NORTH AMERICA

**Australia/New Zealand** t 61 427286832 **Chinese Mainland** t 86 21 3338 4338 India t 91 124 4604000 Japan t 81 3-3586 1996 Korea t 82 2-796-9500 Singapore t 65 6572-9740 Taiwan t 886 2-2716-0338 EUROPE CSEurope@corning.com France t 0800 916 882 Germany t 0800 101 1153 The Netherlands t 020 655 79 28 United Kingdom t 0800 376 8660 **All Other European Countries** t +31 (0) 206 59 60 51

#### LATIN AMERICA grupoLA@corning.com

Brazil t 55 (11) 3089-7400 Mexico t (52-81) 8158-8400

For a listing of trademarks, visit www.corning.com/clstrademarks. All other trademarks are the property of their respective owners. © 2021 Corning Incorporated. All rights reserved. 7/21 CLS-AN-638 REV1